Cargando…

Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study

The impact of ceftriaxone pharmacokinetic alterations on protein binding and PK/PD target attainment still remains unclear. We evaluated pharmacokinetic/pharmacodynamic (PK/PD) target attainment of unbound ceftriaxone in critically ill patients with severe community-acquired pneumonia (CAP). Besides...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gijsen, Matthias, Dreesen, Erwin, Van Daele, Ruth, Annaert, Pieter, Debaveye, Yves, Wauters, Joost, Spriet, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151456/ https://www.ncbi.nlm.nih.gov/pubmed/34064676 http://dx.doi.org/10.3390/antibiotics10050557

Ejemplares similares

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
por: Gijsen, Matthias, et al.
Publicado: (2022)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
por: Gijsen, Matthias, et al.
Publicado: (2021)

Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients
por: Van Daele, Ruth, et al.
Publicado: (2021)

Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review
por: Mertens, Beatrijs, et al.
Publicado: (2023)

Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

Meropenem Stability in Human Plasma at −20 °C: Detailed Assessment of Degradation
por: Gijsen, Matthias, et al.
Publicado: (2021)

Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid
por: Van Daele, Ruth, et al.
Publicado: (2021)

The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation
por: Mertens, Beatrijs, et al.
Publicado: (2022)

Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
por: Kantasiripitak, Wannee, et al.
Publicado: (2020)

Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine
por: Gijsen, Matthias, et al.
Publicado: (2021)

Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review
por: Mertens, Beatrijs, et al.
Publicado: (2022)

External Validation of the Augmented Renal Clearance Predictor in Critically Ill COVID-19 Patients
por: Huang, Chao-Yuan, et al.
Publicado: (2023)

Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?
por: Ewoldt, Tim M J, et al.
Publicado: (2023)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
por: Zahr, Noël, et al.
Publicado: (2022)

1117. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients
por: Kalaria, Shamir N, et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Pharmacodynamics of Ceftriaxone, Ertapenem, Fosfomycin and Gentamicin in Neisseria gonorrhoeae
por: Gubenšek, Urša, et al.
Publicado: (2022)

Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults
por: Gastmans, Heleen, et al.
Publicado: (2022)

Can augmented renal clearance be detected using estimators of glomerular filtration rate?
por: Gijsen, Matthias, et al.
Publicado: (2020)

High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

Reproducibility of fluid status measured by bioelectrical impedance analysis in healthy volunteers: a key requirement to monitor fluid status in the intensive care unit
por: Gijsen, Matthias, et al.
Publicado: (2021)

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
por: Sime, Fekade B., et al.
Publicado: (2019)

Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction
por: Sime, Fekade B., et al.
Publicado: (2019)

Catecholamine pharmacokinetics and pharmacodynamics in critical illness
por: Johnston, AJ, et al.
Publicado: (2003)

Changes in ceftriaxone pharmacokinetics/pharmacodynamics during the early phase of sepsis: a prospective, experimental study in the rat
por: Selmi, Valentina, et al.
Publicado: (2016)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Target Attainment of Tigecycline in Patients with Hepatic Impairment in a Real-World Setting
por: Yang, Xiaoxuan, et al.
Publicado: (2023)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia
por: Ishihara, Noriyuki, et al.
Publicado: (2020)

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
por: Li, Jianguo, et al.
Publicado: (2018)

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
por: Al-Shaer, Mohammad H., et al.
Publicado: (2019)

Population Pharmacokinetic–Pharmacodynamic Modeling and Probability of Target Attainment Analysis of Rocuronium and Sugammadex in Children Undergoing Surgery
por: Grześkowiak, Małgorzata, et al.
Publicado: (2022)

All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches
por: Khalid, Kashaf, et al.
Publicado: (2023)

Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations
por: Jager, Nynke G L, et al.
Publicado: (2020)

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
por: Aguiar Zdovc, Jurij, et al.
Publicado: (2021)

High unbound flucloxacillin fraction in critically ill patients
por: Wallenburg, Eveline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_afvss54u95ncku39fgbu65npnh